Dimethyl fumarate - Medication and Pregnancy KB

Dimethyl fumarate

Exposed non-exposed studies (cohort)

Study	Country Study period	Population source	Exposure definition	Non-exposure definition	Sample size	Rmk
Gold, 2015	Worldwilde Until June 2014	Pregnancies that occurred during the dimethyl fumarate (DMF) clinical development program (including healthy controls and patients with MS, with exposure to placebo, DMF, or glatiramer acetate (GA)).	Pregnancies exposed to dimethyl fumarate (DMF).	unexposed, sick Pregnancies exposed to placebo.	42 / 13	Only data related to clinical trials was used in this meta-analysis, in order to have a control group.
Nguyen (control exposed to IFN), 2019	International 2005 - 2016	Women of child-bearing age (15–45 years inclusive), prospectively enrolled in MSBase with a diagnosis of relapsing-remitting MS (RRMS).	Pregnancies occurring during dimethyl fumarate therapy. (This is a subgroup of exposure among the exposed group considered in the study).	exposed to other treatment, sick Pregnancies occurring during Interferon beta (all) therapy. (This is a subgroup of exposure among the exposed group considered in the study).	17 / 350
Nguyen (control unexposed, sick), 2019	International 2005 - 2016	Women of child-bearing age (15–45 years inclusive), prospectively enrolled in MSBase with a diagnosis of relapsing-remitting MS (RRMS).	Pregnancies occurring during dimethyl fumarate therapy. (This is a subgroup of exposure among the exposed group considered in the study).	unexposed, sick Pregnancies not exposed to disease-modifying therapies (DMTs) (pregnancy occurring within a year of DMT discontinuation or without DMT exposure in the prior year).	17 / 886

Case-control studies (cohort)

Study	Country Study period	Case	Control	Sample size	Rmk

Warning! There are no case-control studies available for this drug.

1 study, not fulfilled eligibility criteria, were excluded. See excluded tab for the list of these studies and reason of exclusion.

master protocol